Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Partial Seizure-Pipeline Review, H1 2015

Partial Seizure-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Partial Seizure-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Partial Seizure-Pipeline Review, H1 2015', provides an overview of the Partial Seizure's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Partial Seizure

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Partial Seizure and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Partial Seizure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Partial Seizure pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Partial Seizure

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Partial Seizure pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Partial Seizure Overview 7

Therapeutics Development 8

Pipeline Products for Partial Seizure-Overview 8

Pipeline Products for Partial Seizure-Comparative Analysis 9

Partial Seizure-Therapeutics under Development by Companies 10

Partial Seizure-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Partial Seizure-Products under Development by Companies 14

Partial Seizure-Companies Involved in Therapeutics Development 15

Catalyst Pharmaceutical Partners, Inc. 15

Eisai Co., Ltd. 16

Marinus Pharmaceuticals, Inc. 17

Novartis AG 18

Pfizer Inc. 19

SciFluor Life Sciences, LLC 20

SK Biopharmaceuticals Co., Ltd. 21

UCB S.A. 22

Partial Seizure-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 25

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 29

brivaracetam-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

CPP-115-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

everolimus-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ganaxolone-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

lacosamide-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

MB-003-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

perampanel-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

pregabalin CR-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

selurampanel-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

SF-0034-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

YKP-3089-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Partial Seizure-Recent Pipeline Updates 55

Partial Seizure-Dormant Projects 75

Partial Seizure-Discontinued Products 76

Partial Seizure-Product Development Milestones 77

Featured News & Press Releases 77

Apr 20, 2015: Important UCB presents data on VIMPAT at the 2015 American Academy of Neurology Meeting 77

Jan 05, 2015: Phase III Trial Of Antiepileptic Drug Perampanel As Adjunctive Therapy In Patients With Refractory Partial-Onset Seizures Conducted In Asia Including Japan And China Meets Primary Endpoint 79

Dec 08, 2014: UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy 80

Apr 25, 2014: Eisai Presents Research on FYCOMPA (perampanel) CIII at The American Academy of Neurology's 66th Annual Meeting 81

Feb 10, 2014: Fycompa to be Resubmitted Early to German Federal Joint Committee for Additional Benefit Assessment 81

Jan 06, 2014: Eisai Announces Launch of Antiepileptic Drug Fycompa in U.S. 82

Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA (perampanel) CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older 83

Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older 84

Nov 20, 2013: New data from UCB's epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society 85

Jul 15, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Vimpat 87

Appendix 88

Methodology 88

Coverage 88

Secondary Research 88

Primary Research 88

Expert Panel Validation 88

Contact Us 88

Disclaimer 89

List of Tables

Number of Products under Development for Partial Seizure, H1 2015 8

Number of Products under Development for Partial Seizure-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Partial Seizure-Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015 15

Partial Seizure-Pipeline by Eisai Co., Ltd., H1 2015 16

Partial Seizure-Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 17

Partial Seizure-Pipeline by Novartis AG, H1 2015 18

Partial Seizure-Pipeline by Pfizer Inc., H1 2015 19

Partial Seizure-Pipeline by SciFluor Life Sciences, LLC, H1 2015 20

Partial Seizure-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 21

Partial Seizure-Pipeline by UCB S.A., H1 2015 22

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Stage and Target, H1 2015 24

Number of Products by Stage and Mechanism of Action, H1 2015 25

Number of Products by Stage and Route of Administration, H1 2015 27

Number of Products by Stage and Molecule Type, H1 2015 28

Partial Seizure Therapeutics-Recent Pipeline Updates, H1 2015 55

Partial Seizure-Dormant Projects, H1 2015 75

Partial Seizure-Discontinued Products, H1 2015 76

List of Figures

Number of Products under Development for Partial Seizure, H1 2015 8

Number of Products under Development for Partial Seizure-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Stage and Top 10 Targets, H1 2015 24

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25

Number of Products by Top 10 Routes of Administration, H1 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27

Number of Products by Stage and Top 10 Molecule Types, H1 2015 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Catalyst Pharmaceutical Partners, Inc.

Eisai Co., Ltd.

Marinus Pharmaceuticals, Inc.

Novartis AG

Pfizer Inc.

SciFluor Life Sciences, LLC

SK Biopharmaceuticals Co., Ltd.

UCB S.A.

Partial Seizure Therapeutic Products under Development, Key Players in Partial Seizure Therapeutics, Partial Seizure Pipeline Overview, Partial Seizure Pipeline, Partial Seizure Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com